Gliaid Forte 4 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 4 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The combination of these two agents offers complementary mechanisms of action, providing effective blood glucose reduction in patients inadequately controlled by diet and exercise alone. Gliaid Forte 4 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. The sustained-release formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is primarily associated with Glimepiride. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of renal function and blood glucose is recommended. This medication should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability.